Additionally, oral administration of CUDC-907 at a dose of 100 mg/Kg induced tumor regression or stability in Daudi non-Hodgkin lymphoma, SU-DHL-4 diffuse large B-cell lymphoma (DLBCL), and KRAS-mutant A549 NSCLC xenografts with decent tolerance. The gene discussed is KRAS; the disease is diffuse large B-cell lymphoma.